Your browser doesn't support javascript.
loading
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Ohgami, Masahiro; Kaburagi, Takayuki; Kurosawa, Atsuhiko; Homma, Masato.
Afiliação
  • Ohgami M; Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba,1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan; Department of Pharmacy, Ibaraki Prefectural Central Hospital, 6528 Koibuchi, Kasama-shi, Ibaraki 309-1793, Japan. Electronic address: s1430
  • Kaburagi T; Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, 6528 Koibuchi, Kasama-shi, Ibaraki, 309-1793, Japan. Electronic address: t-kaburagi@chubyoin.pref.ibaraki.jp.
  • Kurosawa A; Department of Pharmacy, Ibaraki Prefectural Central Hospital, 6528 Koibuchi, Kasama-shi, Ibaraki 309-1793, Japan. Electronic address: t-kurosawa@chubyoin.pref.ibaraki.jp.
  • Homma M; Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba,1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. Electronic address: masatoh@md.tsukuba.ac.jp.
Lung Cancer ; 101: 9-10, 2016 11.
Article em En | MEDLINE | ID: mdl-27794414
Erlotinib, a substrate drug metabolized by the CYP3A4 enzyme, is an epidermal growth factor receptor tyrosine kinase inhibitor used to treat nonsmall cell lung cancer (NSCLC). Concomitant use of erlotinib and the antiepileptic drug phenytoin, an inducer of CYP3A4, may result in a drug-drug interaction accompanied by changes in the blood concentrations of both drugs. We determined the blood concentration of each drug to confirm the interaction between phenytoin and erlotinib in a case of NSCLC with brain metastases. The phenytoin blood concentration (8.2-10.0µg/mL) gradually increased 3-fold (to 24.2µg/mL) 7 months after the start of erlotinib (150mg/d) co-administration. The erlotinib blood concentration which was maintained at 0.15-0.37µg/mL under phenytoin co-administration, increased 12-fold (to 1.77µg/mL) after the stoppage of phenytoin co-administration. The present case revealed that blood phenytoin increased and blood erlotinib decreased subsequent to the interaction of the 2 drugs in the CYP3A4 metabolic enzyme system.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenitoína / Neoplasias Encefálicas / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Interações Medicamentosas / Indutores do Citocromo P-450 CYP1A2 / Cloridrato de Erlotinib Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenitoína / Neoplasias Encefálicas / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Interações Medicamentosas / Indutores do Citocromo P-450 CYP1A2 / Cloridrato de Erlotinib Idioma: En Ano de publicação: 2016 Tipo de documento: Article